2,050 Shares in Eli Lilly and Company (NYSE:LLY) Bought by AssuredPartners Investment Advisors LLC

AssuredPartners Investment Advisors LLC acquired a new stake in shares of Eli Lilly and Company (NYSE:LLY) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 2,050 shares of the company’s stock, valued at approximately $1,583,000.

A number of other institutional investors and hedge funds have also made changes to their positions in LLY. NEOS Investment Management LLC raised its position in shares of Eli Lilly and Company by 29.1% during the 4th quarter. NEOS Investment Management LLC now owns 50,540 shares of the company’s stock valued at $39,017,000 after buying an additional 11,383 shares in the last quarter. Moment Partners LLC purchased a new stake in Eli Lilly and Company during the fourth quarter valued at approximately $1,063,000. Sava Infond d.o.o. purchased a new stake in Eli Lilly and Company during the fourth quarter valued at approximately $7,419,000. WINTON GROUP Ltd lifted its stake in shares of Eli Lilly and Company by 1,093.3% in the 4th quarter. WINTON GROUP Ltd now owns 4,248 shares of the company’s stock valued at $3,279,000 after purchasing an additional 3,892 shares during the last quarter. Finally, Artisan Partners Limited Partnership boosted its holdings in shares of Eli Lilly and Company by 1.4% in the 4th quarter. Artisan Partners Limited Partnership now owns 41,618 shares of the company’s stock worth $32,129,000 after purchasing an additional 574 shares during the period. 82.53% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 1,000 shares of the stock in a transaction dated Thursday, March 13th. The shares were sold at an average price of $818.24, for a total transaction of $818,240.00. Following the completion of the sale, the chief accounting officer now directly owns 5,840 shares of the company’s stock, valued at approximately $4,778,521.60. This represents a 14.62 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 0.13% of the stock is owned by company insiders.

Eli Lilly and Company Stock Down 3.0 %

Shares of Eli Lilly and Company stock opened at $826.84 on Thursday. The company has a debt-to-equity ratio of 2.00, a current ratio of 1.15 and a quick ratio of 0.97. The stock has a market cap of $783.98 billion, a price-to-earnings ratio of 70.61, a PEG ratio of 1.40 and a beta of 0.34. The firm’s 50-day moving average is $841.16 and its two-hundred day moving average is $837.54. Eli Lilly and Company has a 1 year low of $711.40 and a 1 year high of $972.53.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Thursday, February 6th. The company reported $5.32 earnings per share for the quarter, missing the consensus estimate of $5.45 by ($0.13). Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%. As a group, research analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company declared that its Board of Directors has authorized a stock buyback program on Monday, December 9th that allows the company to buyback $15.00 billion in outstanding shares. This buyback authorization allows the company to purchase up to 2% of its stock through open market purchases. Stock buyback programs are generally an indication that the company’s board of directors believes its shares are undervalued.

Analyst Upgrades and Downgrades

LLY has been the subject of a number of analyst reports. Bank of America restated a “buy” rating and issued a $997.00 price target on shares of Eli Lilly and Company in a research report on Tuesday, December 10th. Leerink Partners set a $950.00 target price on shares of Eli Lilly and Company in a report on Friday, January 17th. StockNews.com upgraded shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a report on Friday, February 7th. Berenberg Bank set a $970.00 price objective on shares of Eli Lilly and Company in a research note on Thursday, January 16th. Finally, Wells Fargo & Company boosted their target price on Eli Lilly and Company from $970.00 to $1,100.00 and gave the company an “overweight” rating in a research report on Wednesday, March 5th. Three research analysts have rated the stock with a hold rating and eighteen have given a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $1,009.72.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.